文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

明目颗粒治疗新生血管性年龄相关性黄斑变性的随机对照试验方案

Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-01-19

这是一项双盲、安慰剂对照、随机试验,评估明目颗粒作为玻璃体腔注射雷珠单抗附加治疗对新生血管性年龄相关性黄斑变性(nAMD)的疗效与安全性。主要结局为第24周和第48周最佳矫正视力较基线的平均变化;次要结局包括视网膜中央厚度、出血及渗出面积、中医证候评分、雷珠单抗注射次数和治疗总费用。

要点

  • 明目颗粒作为雷珠单抗附加治疗,采用双盲、安慰剂对照设计验证疗效与安全性。
  • 主要结局为第24周和第48周最佳矫正视力较基线的平均变化。

核心结论

  • 该试验旨在检验明目颗粒作为玻璃体腔注射雷珠单抗附加治疗,能否提高nAMD患者的疗效、安全性及效率,并减少抗VEGF注射次数。

研究设计与样本

  • 双盲、安慰剂对照、随机试验,明目颗粒作为玻璃体腔注射雷珠单抗的附加治疗。
  • 所有参与者接受24周治疗,随后再随访24周。

关键数值与推荐

  • 主要结局为第24周和第48周最佳矫正视力较基线的平均变化。
  • 次要结局包括视网膜中央厚度、视网膜出血和渗出面积、中医证候评分、玻璃体腔雷珠单抗注射平均次数及治疗总费用的平均变化。
  • 安全性指标包括血常规、尿常规、肝功能、肾功能和心电图,从基线至第24周和第48周。

临床怎么用

  • 若试验证实有效,明目颗粒可能作为nAMD抗VEGF治疗的附加方案,以减少注射次数并改善视力结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neovascular age-related macular degeneration (nAMD) is the most common cause of irreversible vision loss and blindness among the older people aged 50 and over. Although anti-vascular endothelial growth factor (anti-VEGF) therapies have resulted in improving patient outcomes, there are limitations associated with these treatments. In China, traditional Chinese medicine (TCM) has been used to treat eye diseases for more than 2000 years. Previous studies have shown that TCM may be beneficial for nAMD patients. However, explicit evidence has not been obtained. The purpose of the present trial is to examine the efficacy and safety of the Mingjing granule, a compound Chinese herbal medicine, for nAMD patients. METHODS/DESIGN: This is a double-blind, placebo-controlled, randomized trial of Mingjing granule as an add-on to intravitreous ranibizumab for nAMD. One hundred eighty nAMD patients from six hospitals in China will be enrolled according to the inclusion and exclusion criteria and randomly allocated into two groups, 90 in each. All participants will receive a 24-week treatment and then be followed up for another 24 weeks. The primary outcome is the mean change of best-corrected visual acuity at week 24 and 48 as compared to the baseline. The secondary outcomes include mean change in central retinal thickness, area of retinal hemorrhage and exudation, and TCM syndrome score, mean number of intravitreal ranibizumab injection, and total cost of the treatment. Indexes of safety include blood regular test, urine regular test, liver function test, renal function test, and electrocardiogram from baseline to weeks 24 and 48. Qualitative control and some standard operating processes will be formed throughout the trial. Any ocular or systemic adverse events will be treated suitably, and related data will be recorded accurately and completely in the case report form. DISCUSSION: Based on previous empirical and animal laboratory studies, this study will address the question of whether Mingjing granule could contribute to improving efficacy, safety, and efficiency with need for fewer intravitreal injections of anti-VEGF, improving compliance and visual outcomes in the management of persons with nAMD. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( http://www.chictr.org.cn ), ChiCTR2000035990 . Registered on 21 August 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Li Y, Liang L, Snellingen T, et al. Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33468208. doi:10.1186/s13063-021-05025-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。